Mallia Geiger

Mallia Geiger

Auto-generated profile, based on publicly available information

Mallia Geiger

Aligning Science Across Parkinson s (ASAP) Collaborative Research Network, Chevy Chase, MD, 20815; Universite Paris-Saclay, INRAE, MGP, 78350 Jouy-en-Josas, France

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 May 2025 in medRxiv
Verified
Preprint
Open access
PDF file
EMElisa Menozzi
Elisa Menozzi
VMVictoria Meslier
Victoria Meslier
YRYani Ren
Yani Ren
MGMallia Geiger
Mallia Geiger
JMJane Macnaughtan
Jane Macnaughtan
ASAnthony Schapira
Anthony Schapira
Summary: Parkinson disease (PD) is a major cause of disability with significant personal and system financial implications 1,2 . GBA1 variants are the commonest genetic risk factor for PD and increase the risk up to 30-fold 3,4 . Why only ∼20% of GBA1 variant carriers develop PD remains unknown. Here, by combining clinical and faecal metagenomics data from PD individuals carrying or not GBA1 variants, carriers of GBA1 variants not manifesting PD symptoms (GBA-NMC) and healthy controls, and using an innovative microbiome analysis, we show that a large component of the gut microbiome evolves from healthy across GBA-NMC towards PD and is strongly correlated with disease progression in patients, and prodromal symptoms suggestive of future development of PD in GBA-NMC. By using species altered in PD and GBA-NMC, we detect healthy individuals with the strongest prodromal PD clinical profile. These findings indicate that gut microbiome alterations can identify individuals with GBA1 variants most prone to develop PD and individuals in the general population that may be progressing towards PD. Healthy nutrition mitigates microbiome alterations associated with disease severity, suggesting that it could modify disease progression in PD patients and decrease the risk of disease development in healthy individuals including those with GBA1 variants.